Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Assets: 2010-2025

Historic Current Assets for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $101.6 million.

  • Anika Therapeutics' Current Assets fell 25.36% to $101.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.6 million, marking a year-over-year decrease of 25.36%. This contributed to the annual value of $113.7 million for FY2024, which is 30.41% down from last year.
  • As of Q3 2025, Anika Therapeutics' Current Assets stood at $101.6 million, which was up 2.29% from $99.3 million recorded in Q2 2025.
  • Anika Therapeutics' Current Assets' 5-year high stood at $177.8 million during Q2 2021, with a 5-year trough of $99.3 million in Q2 2025.
  • Its 3-year average for Current Assets is $136.3 million, with a median of $152.2 million in 2023.
  • Its Current Assets has fluctuated over the past 5 years, first climbed by 7.66% in 2021, then plummeted by 35.92% in 2025.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Current Assets stood at $168.5 million in 2021, then increased by 0.60% to $169.5 million in 2022, then dropped by 3.68% to $163.3 million in 2023, then tumbled by 30.41% to $113.7 million in 2024, then declined by 25.36% to $101.6 million in 2025.
  • Its Current Assets stands at $101.6 million for Q3 2025, versus $99.3 million for Q2 2025 and $102.5 million for Q1 2025.